BriaCell Therapeutics Corp. cotiza a 3.71 USD y tiene una capitalización bursátil de $32M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a person…
| Periodo | 2025-10 | 2025-06 | 2025-03 | 2024-12 |
|---|---|---|---|---|
| Real | $0.04 | $-16.40 | $-23.30 | $-33.00 |
| Estimado | $-12.11 | $-17.60 | $-19.40 | $-12.00 |
| Sorpresa | +100.3% | +6.8% | -20.1% | -175.0% |
| Métrica | BCTX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -151.8% | -40.4% | -111.4% |
| ROA | -121.5% | -32.0% | -89.5% |
| Current Ratio | 5.01 | 2.84 | +2.17 |
| Debt / Equity | — | 0.28 | — |